Group of young people walking together outdoors in a natural setting

Tirzepatide for Teens: SURMOUNT-ADOLESCENTS Trial Finds an 18.5 Percent BMI Drop in 72 Weeks

Editorial Team

For years, a teenager with severe obesity who walked into a paediatric clinic was offered mostly the same three things: advice on food, advice on exercise and a follow-up appointment. Medication was the exception and surgery the last resort. That picture has been shifting since the arrival of GLP-1 drugs. A new trial published in JAMA on November 15 suggests the shift is about to speed up.

The study is called SURMOUNT-ADOLESCENTS. It tested tirzepatide, the active ingredient in Eli Lilly’s Mounjaro and Zepbound, in young people aged 12 to 17. After 72 weeks, those on the drug had reduced their body mass index by an average of 18.5 percent. Those on placebo saw their BMI rise by 0.5 percent. The results were presented at ObesityWeek in National Harbor, Maryland, at the same time.

What the tirzepatide adolescent trial actually tested

The design was a classic phase 3 setup: randomised, double-blind and placebo-controlled. It ran at 31 centres in Canada, the Czech Republic, Israel, Italy, Poland and the United States. A total of 160 adolescents took part, with an average age of 14.6 years and an average BMI of 38.6. About 62 percent were girls. Participants were assigned in a 2:1 ratio to weekly tirzepatide injections or placebo. Everyone also received a healthy lifestyle programme, because no serious obesity treatment for young people works without one.

The dose started low and was increased step by step to the highest level each participant could tolerate, up to a maximum of 15 milligrams. The main goal was the percentage change in BMI after 72 weeks. Because teenagers are still growing, doctors look at BMI relative to age and sex rather than at kilograms alone.

The results in numbers

The difference between the groups was 19 percentage points in favour of tirzepatide. According to the JAMA paper, almost half of the participants on the drug, 48.1 percent, reduced their BMI by at least 20 percent. In the placebo group that figure was 7.9 percent. Contemporary Pediatrics reports that 54 percent of treated adolescents no longer met the BMI threshold for obesity at the end of the trial. Body weight fell by 16.9 percent with tirzepatide, while it rose by 2.2 percent with placebo.

Healio, which covered the ObesityWeek presentation, adds further detail: blood pressure and blood lipids such as triglycerides improved. Body fat measured by DXA scan fell markedly. Contemporary Pediatrics points out that several of these cardiometabolic measures were not statistically adjusted for multiple comparisons, so they should be read as supportive rather than definitive.

Study author Aaron S. Kelly of the University of Minnesota said the results were “by and large” consistent with what had been seen in adults, according to Healio. If you have followed the GLP-1 story in adults, that is the headline: young bodies appear to respond in a similar way.

Side effects: the part you should not skip

The drug is not gentle on the stomach. Gastrointestinal complaints affected 81.5 percent of participants on tirzepatide, compared with 54.9 percent on placebo. Vomiting was reported by about half of the treated group and nausea by a similar share, mostly mild to moderate and concentrated in the phase when doses were being increased. In total, 9.3 percent stopped treatment because of side effects, compared with none in the placebo group. Serious adverse events occurred in 7.4 percent versus 3.9 percent.

Mental health was monitored closely, as it should be in this age group. Reports of depression or suicidal thoughts were slightly more frequent with tirzepatide, 4.6 percent versus 2.0 percent, according to Contemporary Pediatrics. None were classified as serious. The participants concerned all had a prior psychiatric history. Growth and puberty developed as expected in both groups. Claudia Fox of the University of Minnesota said, as quoted by Healio, that there were “no signals of disruption to growth and maturation in this trial.”

What the trial cannot tell you yet

Every good study comes with an honest list of what it leaves open. This one is no exception. With 160 participants it is relatively small. About 83 percent of participants were white and most were already at the final stage of puberty, so the findings may not apply equally to younger or more diverse groups. Only one participant had type 2 diabetes. The trial lasted 72 weeks, which means nobody knows yet what happens over many years or after the treatment is stopped. It was funded by Eli Lilly, which makes tirzepatide.

It is also important to separate the trial from approval. Semaglutide, sold as Wegovy, has been approved by the US Food and Drug Administration for adolescents with obesity since 2022. According to Contemporary Pediatrics, tirzepatide is currently approved for children and teenagers only for type 2 diabetes. Neither of the reports we reviewed mentions a regulatory filing for adolescent obesity. That decision is still open.

From taboo to treatment choice

The American Academy of Pediatrics already recommends offering medication to adolescents aged 12 and older with obesity, alongside lifestyle treatment. In an editorial accompanying the study, William J. Heerman wrote that the question is no longer whether medication has a role in treating childhood obesity but which drug to use and when. That reflects a broader cultural change. Obesity is increasingly understood as a chronic disease with biological drivers rather than a simple matter of willpower.

Our assessment, clearly an interpretation: tirzepatide is likely to become another option for adolescents, but the real debates are only beginning. Who gets access, how long treatment should last, how much it will cost and how families are supported along the way are questions a single trial cannot answer. If you are a parent reading this, the most useful next step is not a search for prescriptions online but a conversation with a paediatrician or an obesity specialist who knows your child.

This article is for general information only and does not replace medical advice. Please talk to a doctor about any questions regarding diagnosis or treatment.

Key facts at a glance

  • What: The SURMOUNT-ADOLESCENTS trial tested weekly tirzepatide injections in 160 adolescents aged 12 to 17 with obesity over 72 weeks.
  • Result: BMI fell by an average of 18.5 percent with tirzepatide while it rose by 0.5 percent with placebo.
  • Side effects: Gastrointestinal complaints affected 81.5 percent of treated participants and 9.3 percent stopped treatment because of side effects.
  • When: The study was published in JAMA on November 15, 2026 and presented at ObesityWeek 2026.
  • Note: for general information only, not medical advice.

FAQ

How much weight did teens lose on tirzepatide in the SURMOUNT-ADOLESCENTS trial?
Adolescents on tirzepatide reduced their BMI by an average of 18.5 percent over 72 weeks. Their body weight fell by 16.9 percent, while it rose in the placebo group.

Is tirzepatide approved for adolescents with obesity?
No approval for adolescent obesity has been announced. The new trial results could form the basis for a future application, but no filing has been reported.

What are the side effects of tirzepatide in adolescents?
The most common side effects were vomiting, nausea and diarrhoea, mostly mild to moderate. About 9 percent of participants stopped treatment because of side effects.